Patent Law (Intellectual Property)
566 U.S. 66 (2012); 132 S. Ct. 1289; 182 L. Ed. 2d 321 (Supreme Court of the United States)
Study notes for Mayo Collaborative Services v. Prometheus Laboratories, Inc.: professor notes, cold call prep, exam angles, and memory aids.
Claims that effectively assert a law of nature, without an inventive concept, are not patent-eligible under 35 U.S.C. § 101.
This case addresses the intersection of patent eligibility and natural laws in patent law. The Supreme Court clarified that while method claims can be eligible for patent protection under 35 U.S.C. § 101, they must not simply claim natural phenomena or laws of nature. The significance of the case lies in its assertion that additional steps in a claim, if they constitute routine or conventional activity known in the field, do not render the claim patentable. This decision highlights the Court's attempts to prevent the patenting of basic scientific truths and encourage innovation rooted in true inventiveness rather than mere application of existing knowledge.
Moreover, the Court's ruling emphasizes the importance of maintaining a balance between providing inventors exclusive rights to their inventions while not broadening those rights to cover fundamental scientific principles that are vital to ongoing research and development. This case serves as a benchmark for future cases on patent eligibility, particularly in the context of medical and biotech innovations, and raises foundational questions about the role of patent law in fostering or hindering scientific advancement.
Mayo's no patent flow - no natural laws can allow for that!
| Case | Distinction |
|---|---|
| Diamond v. Chakrabarty | Chakrabarty involved a genetically modified organism that exhibited distinctive characteristics, thereby being deemed a patentable invention unlike the natural correlation in Mayo. |
| Myriad Genetics, Inc. v. Association for Molecular Pathology | Myriad held that isolated DNA sequences were not naturally occurring, thus distinguishing from Mayo’s claims of a natural correlation related to metabolite levels. |
| KSR Int'l Co. v. Teleflex Inc. | KSR dealt with obviousness rather than patent eligibility, but both cases emphasize the need for an inventive concept beyond what is routine in the field. |
Allowing patents on natural laws would hinder scientific research and discovery, as it would limit access to fundamental knowledge necessary for innovation.
Restricting patent eligibility could stifle investment in medical advancements, as companies might lack the economic incentive to innovate if they cannot secure patent protection.
This case is often examined through questions on patent eligibility, particularly in distinguishing claims that cover natural laws versus those that include transformative actions or improvements. Students may also be asked to analyze the implications of this ruling in the context of biotechnological patents and innovation.